[EN] CRYSTALLINE PEPTIDE EPOXY KETONE PROTEASE INHIBITORS AND THE SYNTHESIS OF AMINO ACID KETO-EPOXIDES<br/>[FR] INHIBITEURS DE PROTÉASE ÉPOXY-CÉTONE PEPTIDIQUE CRISTALLINE, ET SYNTHÈSE DE CÉTO-ÉPOXYDES D'ACIDES AMINÉS
申请人:PROTEOLIX INC
公开号:WO2009045497A1
公开(公告)日:2009-04-09
The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
申请人:Phiasivongsa Pasit
公开号:US08367617B2
公开(公告)日:2013-02-05
The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.